Featured Research

from universities, journals, and other organizations

Oncology: Using electrical signature of cancer cells to get just the right treatment dosage

Date:
March 4, 2013
Source:
Ecole Polytechnique Fédérale de Lausanne
Summary:
Researchers have developed a tool for oncologists using the electrical signature of cancer cells to get just the right treatment dosage for each patient.

EPFL researchers develop a tool for oncologists using the electrical signature of cancer cells to get just the right treatment dosage for each patient.

King Mithridates understood that poison is only as good as the dosage taken. Each day, he ingested small quantities of poison in order to become immunize and escape his court's plotters. Oncologists run up against the same principle when fighting cancer. Sometimes, a small dose of chemotherapy may induce dangerous resistance mechanisms in malignant cells, resulting in relapse. Now, EPFL research published in the journal PLOS ONE reports a tool that could simply and accurately determine the right dose for individual patients.

Dosage, a vital issue

This novel tool, developed by Philippe Renaud's team at EPFL, is based on a very simple principle: a cell's electrical conductivity depends on the level of stress induced by chemotherapy. In broad terms, by measuring a cancerous cell's capacity to conduct electricity, researchers can assess the intensity of the treatment's effect.

"When chemotherapy induces very little stress in cells, particularly after the application of a small dose, there is a problem," says Robert Meissner, a co-author of the study. "Not only is its effect not sufficient to kill the affected cells, but this actually increases the risk of inducing resistance, which will eventually make the treatment ineffective."

This is vital during relapse as cells have already developed resistance mechanisms and sometimes oncologists don't have an effective alternative therapy. Hence, it is fundamental to apply the right dose from the start.

Step towards personalized oncology

The method developed at EPFL could help doctors make more patient-specific decisions. "We fully subscribe to the trend of personalized medicine," explains Philippe Renaud. "By making a simple biopsy, oncologists could test the way a particular patient's cells respond to different types of treatments at various doses."

The tool, which was designed for a clinical environment, provides a simple and fast analysis without affecting the treated cells. Unlike methods based on biomarkers, which kill cells and are extremely strenuous to perform, the EPFL technology could be implemented easily in a medical environment. In fact, scientists have already tested it on malignant breast cells treated with a standard drug, doxorubicin.

The EPFL team is currently in discussion with oncologists to continue jointly developing their procedure. Within a few months, researchers say, a startup company will likely be created to help bring the laboratory work into the hospital setting.


Story Source:

The above story is based on materials provided by Ecole Polytechnique Fédérale de Lausanne. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bilge Eker, Robert Meissner, Arnaud Bertsch, Kapil Mehta, Philippe Renaud. Label-Free Recognition of Drug Resistance via Impedimetric Screening of Breast Cancer Cells. PLoS ONE, 2013; 8 (3): e57423 DOI: 10.1371/journal.pone.0057423

Cite This Page:

Ecole Polytechnique Fédérale de Lausanne. "Oncology: Using electrical signature of cancer cells to get just the right treatment dosage." ScienceDaily. ScienceDaily, 4 March 2013. <www.sciencedaily.com/releases/2013/03/130304211458.htm>.
Ecole Polytechnique Fédérale de Lausanne. (2013, March 4). Oncology: Using electrical signature of cancer cells to get just the right treatment dosage. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/03/130304211458.htm
Ecole Polytechnique Fédérale de Lausanne. "Oncology: Using electrical signature of cancer cells to get just the right treatment dosage." ScienceDaily. www.sciencedaily.com/releases/2013/03/130304211458.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins